At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jul 29, 2026 at 16:30 ET
Dyne Therapeutics reported Q2 2026 net loss of $1.08 per share, slightly narrower than the $0.97 loss in Q2 2025 but above the consensus estimate of -$0.75. The key catalyst is the FDA acceptance of the BLA for z-rostudirsen in DMD with Priority Review and a PDUFA date of January 21, 2027, alongside completion of enrollment in the ACHIEVE trial for DM1. The company also completed a $431M public offering and expanded its debt facility to $400M, extending cash runway into Q2 2028.
- BLA for z-rostudirsen (exon 51 DMD) accepted with Priority Review; PDUFA date January 21, 2027
- Completed enrollment of 71 participants in ACHIEVE registrational expansion cohort for DM1; topline data Q1 2027
- IND cleared for DYNE-302 in FSHD; Phase 1 trial planned
- Completed $431M public offering (21M shares at $20.50) in July 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access